RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase not stated

Registered title, quoted from ClinicalTrials.gov

A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 27 hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 27

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteChongqing University Cancer Hospital重庆大学附属肿瘤医院ChongqingHospital page
  2. Study siteFirst Affiliated Hospital of Anhui Medical University安徽医科大学第一附属医院HefeiHospital page
  3. Study siteFirst Affiliated Hospital of Chongqing Medical University重庆医科大学附属第一医院ChongqingHospital page
  4. Study siteFirst Affiliated Hospital of Xi'an Jiaotong University西安交通大学第一附属医院Xi'anHospital page
  5. Study siteFirst Affiliated Hospital of Xiamen University厦门大学附属第一医院XiamenHospital page
  6. Study siteFirst Hospital of Jilin University吉林大学第一医院ChangchunHospital page
  7. Study siteFourth Hospital of Hebei Medical University河北医科大学第四医院ShijiazhuangHospital page
  8. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page
  9. Study siteGuizhou Provincial People's Hospital贵州省人民医院GuiyangHospital page
  10. Study siteHainan General Hospital / Hainan Medical University hospitals海南医学院附属医院/海南省人民医院HaikouHospital page
  11. Study siteHarbin Medical University Cancer Hospital哈尔滨医科大学附属肿瘤医院HarbinHospital page
  12. Study siteHenan Cancer Hospital河南省肿瘤医院ZhengzhouHospital page
  13. Study siteHubei Cancer Hospital湖北省肿瘤医院WuhanHospital page
  14. Study siteJiangsu Province Hospital江苏省人民医院(南医大一附院)NanjingHospital page
  15. Study siteJiangxi Cancer Hospital江西省肿瘤医院NanchangHospital page
  16. Study siteLiaoning Cancer Hospital & Institute辽宁省肿瘤医院ShenyangHospital page
  17. Study siteNorthern Jiangsu People's Hospital江苏省苏北人民医院YangzhouHospital page
  18. Study sitePeking University First Hospital北京大学第一医院BeijingHospital page
  19. Study sitePeking University Third Hospital北京大学第三医院BeijingHospital page
  20. Study siteShandong Provincial Hospital山东省立医院JinanHospital page
  21. Study siteShanxi Cancer Hospital山西省肿瘤医院TaiyuanHospital page
  22. Study siteSichuan Provincial People's Hospital四川省人民医院ChengduHospital page
  23. Study siteSun Yat-sen Memorial Hospital中山大学孙逸仙纪念医院GuangzhouHospital page
  24. Study siteTaizhou Hospital, Wenzhou Medical University温州医科大学附属台州医院TaizhouHospital page
  25. Study siteWeifang People's Hospital潍坊市人民医院WeifangHospital page
  26. Study siteZhongshan Hospital, Fudan University复旦大学附属中山医院ShanghaiHospital page
  27. Study siteZhujiang Hospital南方医科大学珠江医院GuangzhouHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07347600, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 2

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (2 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Participants must be diagnosed with endocrine-resistant, PIK3CA-mutated, HR+/HER2- LA/mBC, following recurrence on or after completing adjuvant endocrine therapy

    Inclusion criterion 1

    Participants for which the treatment with inavolisib is not indicated per prescribing information. If the participant starts palbociclib and fulvestrant first, and starts inavolisib after getting a PIK3CA mutation-positive test result later, the palbociclib and fulvestrant will not be deemed as a different line of therapy. However, the medical order of PIK3CA mutation test must be made before or at the same time with the prescription of palbociclib and fulvestrant

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function; scans and measurable lesions; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07347600, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Participants must be diagnosed with endocrine-resistant, PIK3CA-mutated, HR+/HER2- LA/mBC, following recurrence on or after completing adjuvant endocrine therapy
  • Participants must receive the treatment of inavolisib for the first time
  • PIK3CA mutation status should be detected by a National Medical Products Administration (NMPA)-approved or validated assay [Polymerase Chain Reaction (PCR) or Next Generation Sequencing (NGS)] by testing of blood or tumor tissue prior to the initiation of inavolisib

Exclusion Criteria:

  • Participants for which the treatment with inavolisib is not indicated per prescribing information. If the participant starts palbociclib and fulvestrant first, and starts inavolisib after getting a PIK3CA mutation-positive test result later, the palbociclib and fulvestrant will not be deemed as a different line of therapy. However, the medical order of PIK3CA mutation test must be made before or at the same time with the prescription of palbociclib and fulvestrant
  • Participants not receiving treatment for LA/mBC with inavolisib according to standard of care (SOC) and in line with the current summary of product characteristics (SPC)/local labeling
  • At the investigator's discretion, any reason that makes the participant hard to follow up or unsuitable to participate in the study

Quoted from ClinicalTrials.gov, NCT07347600, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07347600, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07347600